News headlines about MEI Pharma (NASDAQ:MEIP) have trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. MEI Pharma earned a news sentiment score of 0.07 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 47.8695357357875 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

These are some of the news stories that may have impacted Accern’s scoring:

Shares of MEI Pharma (NASDAQ MEIP) opened at $2.29 on Friday. MEI Pharma has a 52 week low of $1.34 and a 52 week high of $3.26.

MEI Pharma (NASDAQ:MEIP) last issued its quarterly earnings results on Tuesday, September 5th. The company reported ($0.12) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.15) by $0.03. The firm had revenue of $0.45 million during the quarter, compared to analysts’ expectations of $0.60 million. MEI Pharma had a negative net margin of 3,105.30% and a negative return on equity of 74.68%. equities research analysts predict that MEI Pharma will post -1.05 earnings per share for the current year.

Separately, Zacks Investment Research cut shares of MEI Pharma from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 8th.

TRADEMARK VIOLATION WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact MEI Pharma (MEIP) Stock Price” was first reported by Watch List News and is the property of of Watch List News. If you are accessing this piece on another website, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The original version of this piece can be accessed at

MEI Pharma Company Profile

MEI Pharma, Inc is an oncology company. The Company is focused on the clinical development of drugs and therapies for treatment of cancer. The Company’s portfolio of clinical drug candidates includes Pracinostat, ME-344 and PWT143. Pracinostat is an orally available histone deacetylase (HDAC) inhibitor indicated for the treatment of advanced hematologic diseases, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

Insider Buying and Selling by Quarter for MEI Pharma (NASDAQ:MEIP)

Receive News & Ratings for MEI Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEI Pharma Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.